Market Performance - The medical device sector increased by 1.33% on September 5, with JinHao Medical leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Top Gainers in Medical Device Sector - JinHao Medical (872925) closed at 31.25, up 10.00% with a trading volume of 31,400 shares and a transaction value of 93.90 million yuan [1] - AoJing Medical (688613) closed at 21.50, up 9.19% with a trading volume of 87,400 shares and a transaction value of 182 million yuan [1] - BoXun Bio (836504) closed at 31.24, up 4.55% with a trading volume of 18,000 shares and a transaction value of 55.51 million yuan [1] Top Losers in Medical Device Sector - JiMin Health (603222) closed at 10.51, down 8.77% with a trading volume of 896,400 shares and a transaction value of 947 million yuan [2] - SaiNuo Medical (688108) closed at 34.18, down 7.25% with a trading volume of 736,700 shares and a transaction value of 246.2 million yuan [2] - TouJing Life (300642) closed at 27.12, down 4.88% with a trading volume of 245,300 shares and a transaction value of 63.9 million yuan [2] Capital Flow in Medical Device Sector - The medical device sector experienced a net outflow of 295 million yuan from institutional investors, while retail investors saw a net inflow of 299 million yuan [2][3] - The top net inflows from retail investors included companies like LePu Medical (300003) with a net inflow of 16.38 million yuan [3]

Group 1 - The company will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025, from 15:00 to 17:00 [1][2] - The briefing will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live streaming and online interaction [1][2] - Investors can submit questions from September 10 to September 16, 2025, before 16:00, through the Roadshow Center website or via the company's email [3] Group 2 - Key participants in the briefing include Chairman Eric Gang Hu, General Manager and Secretary of the Board Qiu Zhiye, and Chief Financial Officer Wang Ling [2] - After the briefing, investors can view the meeting details and main content on the Shanghai Stock Exchange Roadshow Center [4]

关于参加 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688613 证券简称：奥精医疗 公告编号：2025-049 奥精医疗科技股份有限公司 会议召开时间：2025 年 09 月 17 日（星期三） 15:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 09 月 10 日 （星期三） 至 09 月 16 日 （星 期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 information@allgensmed.com 进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 奥精医疗科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深 入地了解公司 2025 年半年 ...

Core Viewpoint - Aojing Medical (688613) has experienced a decline in stock price and performance metrics, with significant changes in shareholder structure and upcoming corporate actions [1][2][3][4]. Stock Performance - As of August 29, 2025, Aojing Medical's stock closed at 20.0 CNY, down 4.4% from the previous week [1]. - The stock reached a high of 21.26 CNY and a low of 19.15 CNY during the week [1]. - The company's current market capitalization is 2.74 billion CNY, ranking 115th in the medical device sector and 4666th in the A-share market [1]. Financial Performance - For the first half of 2025, Aojing Medical reported a main revenue of 100 million CNY, a slight decrease of 0.2% year-on-year [2]. - The net profit attributable to shareholders was 7.9753 million CNY, down 13.52% year-on-year [2]. - The second quarter of 2025 showed a main revenue of 57.5772 million CNY, an increase of 8.88% year-on-year, with a net profit of 6.9338 million CNY, up 203.59% year-on-year [2]. Shareholder Changes - As of June 30, 2025, the number of shareholders increased to 8543, reflecting an 8.07% rise since March 31, 2025 [1]. - The average number of shares held per shareholder decreased from 17,100 to 16,000, with an average holding value of 306,600 CNY [1]. Corporate Announcements - Aojing Medical's second supervisory board meeting on August 29, 2025, approved several key proposals, including the half-year report and the use of idle fundraising for operational needs [3]. - A special shareholders' meeting is scheduled for September 15, 2025, to discuss the re-election of a non-independent director [3]. - BioVeda China RMB Investment Limited, holding 5.28% of the company, plans to reduce its stake by up to 1% between September 22 and December 22, 2025 [4].

Core Insights - Aojing Medical (688613) reported a net profit decline of 13.52% year-on-year for the first half of 2025, with total revenue of 100 million yuan, a slight decrease of 0.2% compared to the previous year [1] - The second quarter showed a revenue increase of 8.88% year-on-year, with a significant net profit increase of 203.59% [1] Financial Performance - Total revenue for 2025 was 100 million yuan, unchanged from 2024, with a net profit of 797.53 million yuan, down 13.52% [1] - Gross margin decreased to 63.12%, down 17.75% year-on-year, while net margin improved to 5.53%, up 12.23% [1] - Total expenses (selling, administrative, and financial) amounted to 52.27% of revenue, a decrease of 13.41% year-on-year [1] Key Metrics - Earnings per share (EPS) decreased to 0.06 yuan, down 14.29% year-on-year, while operating cash flow per share improved to -0.03 yuan, an increase of 55.48% [1] - The company's return on invested capital (ROIC) has been historically low, with a median of 9.28% since its listing, and a particularly poor ROIC of -1.21% in 2024 [3] - The company maintains a healthy cash position, indicating good solvency [3]

Core Viewpoint - BioVeda China RMB Investment Limited plans to reduce its shareholding in Aojing Medical Technology Co., Ltd. due to personal financial arrangements, with a maximum reduction of 1,355,515 shares, representing 1% of the total shares [1] Shareholder Reduction Plan - As of the announcement date, BioVeda holds 7,239,358 shares, accounting for 5.28% of Aojing Medical's total shares [1] - The reduction will occur through centralized bidding and block trading, starting from September 22, 2025, to December 22, 2025 [1] - The reason for the reduction is stated as personal financial arrangements [1] Shareholder Background - BioVeda is identified as a controlling shareholder and holds more than 5% of the shares [1] - In the past 12 months, BioVeda has reduced its holdings by 345,087 shares, representing 0.25% of the total shares, at a price range of 17.00 to 17.19 yuan per share [1] Compliance with Lock-up Commitments - The planned reduction is consistent with previous commitments made by BioVeda regarding the lock-up of shares for 12 months post-IPO [2] - There are no other arrangements or commitments that conflict with the current reduction plan [2]

Summary of Key Points Core Viewpoint - On August 29, Guizhou Moutai announced plans for a significant share buyback, while 13 other listed companies disclosed their intentions to reduce shareholdings [1][2]. Group 1: Guizhou Moutai - The controlling shareholder of Guizhou Moutai intends to increase its stake by purchasing shares worth between 3 billion to 3.3 billion yuan [2]. Group 2: Companies Reducing Holdings - Several companies announced share reductions, including: - Siyi Information: Five actual controllers plan to reduce their holdings by up to 3% [2]. - Galaxy Magnetics: Director He Jinzhu plans to sell no more than 460,000 shares [2]. - Pinwo Food: The controlling shareholder Wang Mu intends to reduce his stake by up to 3% [2]. - Dike Co., Ltd.: Shareholders from Wuxi Diyin Technology, Wuxi Saide Technology, and Wuxi Shanghui Jia plan to reduce their holdings by up to 1% [2]. - Hengguang Co., Ltd.: Shareholder Xiangjiang Investment plans to reduce its stake by up to 2.99% [2]. - New Open Source: Deputy General Manager Zou Xiaowen plans to sell no more than 125,200 shares [2]. - Nawei Technology: Shareholders intend to reduce their holdings by up to 2.6759% [2]. - Aojing Medical: Shareholders plan to reduce their stake by up to 1% [2]. - Huasheng Tiancai: Director Wang Weihang and Supervisor Qian Jiying plan to reduce their holdings by up to 0.9984% [2]. - Kosen Technology: Director Tan Chai Hau plans to reduce his stake by up to 0.0615% [2]. - Aorite: Tian Tai Bolong plans to reduce its holdings by up to 0.54% [2]. - Zhejiang Wen Film: Shareholder Qian Wenlong plans to reduce his stake by up to 0.4308% [2]. - Chenxin Pharmaceutical: Shareholder Shi Sihua plans to reduce his holdings by up to 1% [2].

Group 1 - The core viewpoint of the article highlights the financial performance of Aojing Medical, indicating a slight decline in revenue and profit for the first half of 2025 compared to the previous year [1] Group 2 - Aojing Medical reported an operating income of approximately 100 million yuan for the first half of 2025, representing a year-on-year decrease of 0.2% [1] - The net profit attributable to shareholders was about 7.98 million yuan, reflecting a year-on-year decline of 13.52% [1] - The basic earnings per share stood at 0.06 yuan, down 14.29% year-on-year [1] - As of the report date, Aojing Medical's market capitalization was 2.7 billion yuan [2]

Summary of Key Points Core Viewpoint - On August 29, 2023, Guizhou Moutai announced plans for significant stock buybacks, while 13 other listed companies disclosed their intentions to reduce shareholdings, indicating a mixed sentiment in the market regarding stock ownership adjustments [1][2]. Group 1: Stock Buybacks - Guizhou Moutai's controlling shareholder intends to increase their stake by purchasing between 3 billion to 3.3 billion yuan worth of company shares [2]. Group 2: Stock Reductions - Several companies announced share reductions, including: - Sayi Information: Five actual controllers plan to reduce their holdings by up to 3% [2]. - Galaxy Magnetics: Director He Jinzhu plans to sell no more than 460,000 shares [2]. - Pinwo Food: The controlling shareholder Wang Mu intends to reduce his stake by up to 3% [2]. - Dike Co., Ltd.: Shareholders from Wuxi Diyin Technology, Wuxi Saide Technology, and Wuxi Shanghui Jia plan to reduce their holdings by up to 1% [2]. - Hengguang Co., Ltd.: Shareholder Xiangjiang Investment plans to reduce holdings by up to 2.99% [2]. - New Open Source: Deputy General Manager Zou Xiaowen plans to sell no more than 125,200 shares [2]. - Nawei Technology: Shareholders intend to reduce their holdings by up to 2.6759% [2]. - Aojing Medical: Shareholders plan to reduce their holdings by up to 1% [2]. - Huasheng Tiancai: Director Wang Weihang and Supervisor Qian Jiying plan to reduce their holdings by up to 0.9984% [2]. - Kosen Technology: Director Tan Chai Hau plans to reduce holdings by up to 0.0615% [2]. - Aoyue Technology: Tian Tai Bolong plans to reduce holdings by up to 0.54% [2]. - Zhejiang Wen Film: Shareholder Qian Wenlong plans to reduce holdings by up to 0.4308% [2]. - Chenxin Pharmaceutical: Shareholder Shi Sihua plans to reduce holdings by up to 1% [2].

Core Viewpoint - BioVeda plans to reduce its stake in Aojing Medical (688613.SH) by up to 1,355,515 shares, representing 1% of the total shares, due to its own financial arrangements [1] Group 1 - Aojing Medical has received a notification from BioVeda regarding its share reduction plan [1] - The reduction will be executed through centralized bidding and block trading based on market conditions [1] - The total number of shares BioVeda intends to sell is capped at 1,355,515 [1]